AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Newborn Screening and Early Diagnosis of AADC Deficiency in the Ligurian Population

Recruitingn/aAges 0 Days - 3 DaysAllIstituto Giannina Gaslini
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Aromatic L-amino acid decarboxylase deficiency (AADC-D) is a rare genetic disorder that affects the production of neurotransmitters in the brain and can cause severe neurological and developmental problems. Early diagnosis may allow affected children to be referred promptly for specialist care and evaluation for available treatments, including gene therapy. The purpose of this study is to develop a newborn screening protocol for AADC-D in the neonatal population of Liguria, Italy, and to estimate the incidence of the disease in this population. The study will also establish reference values for 3-O-methyldopa (3-OMD), a biochemical marker used to identify newborns who may have AADC-D, and determine appropriate screening cut-off values. Approximately 16,000 newborns born in participating hospitals in Liguria will be included in the study. After informed consent is obtained from their pa

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Newborns born in participating birth centers in the Liguria region, Italy. * Written informed consent provided by a parent or legal caregiver after reading the study information sheet. Exclusion Criteria: * Absence of written informed consent from a parent or legal caregiver.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

10 sites
Ospedale Galliera
Genova, Italy
IRCCS Policlinico San Martino
Genova, Italy
Ospedale Villa Scassi
Genova, Italy
IRCCS Istituto G. Gaslini
Genova, Italy
Ospedale Evangelico
Genova, Italy
IRCCS Istituto G. Gaslini
Genova, Italy
Ospedale La Spezia
La Spezia, Italy
Ospedale Lavagna
Lavagna, Italy

โ€ฆand 2 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy